- Home
- BIPC vs AKRO Comparison
BIPC vs AKRO Comparison
Compare BIPC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIPC | AKRO |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BIPC | AKRO |
|---|---|---|
| Price | $45.54 | $54.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $53.00 | ★ $73.56 |
| AVG Volume (30 Days) | 557.1K | ★ 2.4M |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,656,000,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.47 | N/A |
| 52 Week Low | $32.08 | $21.34 |
| 52 Week High | $47.71 | $58.40 |
Technical Indicators
Market Signals| Indicator | BIPC | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 68.63 |
| Support Level | $45.89 | $54.30 |
| Resistance Level | $47.59 | $54.70 |
| Average True Range (ATR) | 1.04 | 0.17 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 49.90 | 71.07 |
Price Performance
Historical ComparisonAbout BIPC Brookfield Infrastructure Corporation
Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom and the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.